Smoking cessation improves cardiometabolic risk in overweight and obese subjects treated with varenicline and dietary counseling.
Study Goal
The researchers aimed to determine whether dietary counseling could mitigate adverse cardiometabolic effects (e.g., weight gain, dyslipidemia, blood pressure changes) in overweight and obese smokers attempting to quit.
Results Summary
Dietary counseling during smoking cessation led to improved triglyceride levels and diastolic blood pressure in quitters without significant weight gain, though other cardiometabolic markers and insulin resistance showed no difference between quitters and continuing smokers. The study combined low-carbohydrate and low-fat diet groups due to similar outcomes.
Population
Overweight and obese smokers (BMI 25-40 kg/m², ≥10 cigarettes/day).
Effective Dosage
Not specified (dietary counseling focused on low-carbohydrate or low-fat diets).
Duration
12 weeks.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
low-carbohydrate or low-fat diet with varenicline | no change | changes in metabolic risk factors | smokers (≥10 cigarettes/day) with BMI 25-40 kg/m2 | - | did not differ | #1 |
low-carbohydrate or low-fat diet with varenicline | no change | weight change | validated quitters vs continuing smokers | -0.1 ± 3.0 kg vs 0.3 ± 3.1 kg | similar | #2 |
low-carbohydrate or low-fat diet with varenicline | no change | change in waist circumference | validated quitters vs continuing smokers | -2.0 ± 3.8 cm vs -0.9 ± 3.9 cm | similar | #3 |
low-carbohydrate or low-fat diet with varenicline | decrease | triglyceride concentrations | quitters | -0.16 ± 0.52 mmol/l vs 0.21 ± 0.95 mmol/l | more favorable | #4 |
low-carbohydrate or low-fat diet with varenicline | decrease | diastolic blood pressure | quitters | -0.9 ± 6 mmHg vs 1.9 ± 8 mmHg | more favorable | #5 |
low-carbohydrate or low-fat diet with varenicline | no change | changes in other cardiometabolic risks | quitters and continuous smokers | - | did not differ | #6 |
low-carbohydrate or low-fat diet with varenicline | no change | HOMA-IR | quitters and continuous smokers | - | did not differ | #7 |
low-carbohydrate or low-fat diet with varenicline | no change | energy intake | quitters and continuous smokers | - | did not differ | #8 |
low-carbohydrate or low-fat diet with varenicline | no change | resting metabolic rate | quitters and continuous smokers | - | did not differ | #9 |
dietary intervention | decrease | dyslipidemia | overweight and obese smokers | - | improved | #10 |
dietary intervention | decrease | blood pressure | overweight and obese smokers | - | improved | #11 |
dietary intervention | no change | weight | quitters | - | no early weight gain was seen | #12 |
BACKGROUND AND AIM: Weight gain after stopping smoking potentially counteracts improvements in cardiometabolic risks. We investigated changes in metabolic syndrome (MetS) components and homeostasis assessment model insulin resistance (HOMA-IR) in smokers given dietary counseling during their quit attempt. METHODS AND RESULTS: Smokers (≥10 cigarettes/day) with BMI 25-40 kg/m2 were randomized to a low-carbohydrate or low-fat diet and treated with a standard course of varenicline for 12 weeks. Quitters were assessed according to the Russell standard (≤5 cigarettes after the quit date) validated with expired breath carbon monoxide (CO) < 10 ppm. Of 122 randomized participants, 108 (89%) completed clinical and laboratory assessments at 12 weeks. As changes in metabolic risk factors did not differ between dietary groups, we combined the groups to compare quitters to continuing smokers. We found similar weight change among 78 validated quitters as 30 continuing smokers (-0.1 ± 3.0 kg vs 0.3 ± 3.1 kg; p = 0.7) and change in waist circumference (-2.0 ± 3.8 cm vs -0.9 ± 3.9 cm; p = 0.2). Changes in triglyceride concentrations (-0.16 ± 0.52 mmol/l vs 0.21 ± 0.95 mmol/l; p = 0.015) and diastolic blood pressure (-0.9 ± 6 mmHg vs 1.9 ± 8 mmHg; p = 0.039) were more favorable in quitters. Changes in other cardiometabolic risks and HOMA-IR did not differ between quitters and continuous smokers, nor did energy intake or resting metabolic rate. CONCLUSION: Dyslipidemia and blood pressure improved and no early weight gain was seen in quitters, suggesting that dietary intervention can mitigate some of the effects of stopping smoking on cardiometabolic risk factors in overweight and obese smokers. CLINICAL TRIALS REGISTRATION: NCT01069458.